The Food and Drug Administration (FDA) has approved Foundation Medicine’s liquid biopsy test. The test can be used as a companion diagnostic for FDA-approved precision therapies for treatment of prostate cancer and non-small cell lung cancer (NSCLC).
The use of the liquid biopsy, mutation detection from circulating tumour DNA (ctDNA), has been an area of active research. Obtaining sufficient tumour tissue for testing can be quite challenging, particularly when there is an insufficient biopsy sample and invasive procedures pose a health risk to the patients.
